Evidence map›Paper›PMID 38619110›Full record

ArticleeLife2024

A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1.

Swati Jain, Gherman Uritskiy, Marthandan Mahalingam, Himanshu Batra, Subhash Chand, Hung V Trinh, Charles Beck, Woong-Hee Shin, Wadad Alsalmi, Gustavo Kijak and 8 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Swati JainBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.ORCID https://orcid.org/0000-0002-8625-8218
Gherman UritskiyBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.
Marthandan MahalingamBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.
Himanshu BatraBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.
Subhash ChandBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.
Hung V TrinhHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.
Charles BeckDepartment of Molecular Genetics and Microbiology, Duke University, Durham, United States.
Woong-Hee ShinDepartment of Biological Sciences, Purdue University, West Lafayette, United States.
Wadad AlsalmiBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.
Gustavo KijakHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.
Leigh A EllerHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.
Jerome KimLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States.
Daisuke KiharaDepartment of Biological Sciences, Purdue University, West Lafayette, United States.
Sodsai TovanabutraHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.
Guido FerrariDepartment of Molecular Genetics and Microbiology, Duke University, Durham, United States.
Merlin L RobbHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.
Mangala RaoLaboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States.
Venigalla B RaoBacteriophage Medical Research Center, Department of Biology, The Catholic University of America, Washington, United States.ORCID https://orcid.org/0000-0002-0777-6587
Catholic University of America · USHenry M. Jackson Foundation · USDuke University · USWalter Reed Army Institute of Research · USPurdue University West Lafayette · USSunchon National University · KR

Funding

Single Dose, Multivalent, Anthrax Plague Vaccines using Bacteriophage T4 NanopartR01AI111538 · NIAID · CATHOLIC UNIVERSITY OF AMERICA · PI RAO, VENIGALLA B. · 2014 to 2018
$3.6M
Potent Phage T4 Derived V2 Immunogens as HIV VaccinesR01AI102725 · NIAID · CATHOLIC UNIVERSITY OF AMERICA · PI RAO, VENIGALLA B. · 2012 to 2015
$1.7M
Building protein structure models for intermediate resolution cryo-electron microscopy mapsR01GM133840 · NIGMS · PURDUE UNIVERSITY · PI KIHARA, DAISUKE · 2020 to 2023
$1.6M
Structural Modeling of Multifarious Protein ComplexesR01GM123055 · NIGMS · PURDUE UNIVERSITY · PI KIHARA, DAISUKE · 2017 to 2020
$1.2M
NIAID NIH HHS R01 AI102725NIAID NIH HHS R01 AI111538NIGMS NIH HHS R01 GM123055NIGMS NIH HHS R01 GM133840NIH HHS R01GM123055NIH HHS R01GM133840
6 · The paper itself

Abstract

A productive HIV-1 infection in humans is often established by transmission and propagation of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of variants during the lifetime of infection. An effective HIV-1 vaccine should elicit broad immune responses in order to block the entry of diverse T/F viruses. Currently, no such vaccine exists. An in-depth study of escape variants emerging under host immune pressure during very early stages of infection might provide insights into such a HIV-1 vaccine design. Here, in a rare longitudinal study involving HIV-1 infected individuals just days after infection in the absence of antiretroviral therapy, we discovered a remarkable genetic shift that resulted in near complete disappearance of the original T/F virus and appearance of a variant with H173Y mutation in the variable V2 domain of the HIV-1 envelope protein. This coincided with the disappearance of the first wave of strictly H173-specific antibodies and emergence of a second wave of Y173-specific antibodies with increased breadth. Structural analyses indicated conformational dynamism of the envelope protein which likely allowed selection of escape variants with a conformational switch in the V2 domain from an α-helix (H173) to a β-strand (Y173) and induction of broadly reactive antibody responses. This differential breadth due to a single mutational change was also recapitulated in a mouse model. Rationally designed combinatorial libraries containing 54 conformational variants of V2 domain around position 173 further demonstrated increased breadth of antibody responses elicited to diverse HIV-1 envelope proteins. These results offer new insights into designing broadly effective HIV-1 vaccines.

Indexed as

AIDS VaccinesDermatitisHIV-1AnimalsAntibodiesAntibody FormationAntigens, ViralHumansLongitudinal StudiesMiceAIDS VaccinesAntibodiesAntigens, Viralcombinatorial vaccinecross-reactive antibodieshiv escapeinfectious diseasemicrobiologymousev2 mutation

Identifiers

PMID38619110
PMCPMC11018346
OpenAlexW4391169378

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.